What is new in 2019 ESC Clinical Practice Guidelines? Guidelines for diabetes, pre-diabetes and cardiovascular disease Review article
Article Sidebar
Published:
Dec 31, 2019
Keywords:
diabetes mellitus, cardiovascular diseases, guidelines
Main Article Content
Abstract
The increasing prevalence of diabetes with the novel treatment opportunities, shows the relevance of an update to the earlier guidelines. The review discusses selected changes in the new ESC 2019 guidelines on the managment of diabetes, pre-diabetes and cardiovascular diseases. The focus is on proper cardiovascular risk management, new drug classes and setting treatment goals.
Article Details
How to Cite
Zamecka , E., Ładak, P., Mrozińska, A., Sobieszek, A., & Kuch , M. (2019). What is new in 2019 ESC Clinical Practice Guidelines? Guidelines for diabetes, pre-diabetes and cardiovascular disease. Medycyna Faktow (J EBM), 12(4(45), 358-361. https://doi.org/10.24292/01.MF.0419.9
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Sarwar N., Gao P., Seshasai S.R. et al.; Emerging Risk Factors Collaboration: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
2. Turnbull F.M., Abraira C., Anderson R.J. et al.; Control Group: Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
3. Ray K.K., Seshasai S.R., Wijesuriya S. et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
4. Nathan D.M., Bayless M., Cleary P. et al.; DCCT/EDIC Research Group: Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 2013; 62: 3976-3986.
5. Seferovic P.M., Paulus W.J.: Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur. Heart J. 2015; 36: 1718-1727.
2. Turnbull F.M., Abraira C., Anderson R.J. et al.; Control Group: Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
3. Ray K.K., Seshasai S.R., Wijesuriya S. et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
4. Nathan D.M., Bayless M., Cleary P. et al.; DCCT/EDIC Research Group: Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 2013; 62: 3976-3986.
5. Seferovic P.M., Paulus W.J.: Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur. Heart J. 2015; 36: 1718-1727.